Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.

ABSTRACT: BACKGROUND:Immunosuppressive cytokines have the potential to promote prostate cancer progression. Assessing their longitudinal changes may implicate mechanisms of progression, treatment resistance, and suggest new therapeutic targets. METHODS:Thirty-seven men with biochemically recurrent (BCR) prostate cancer who received 6 months of androgen deprivation therapy (ADT) and were monitored until the time to prostate-specific antigen progression (TTPP) were identified from a completed phase III trial (NCT00020085). Serum samples were archived at baseline, 3 months after ADT, and at TTPP. Cytokine concentrations were quantified using a 36-parameter electrochemiluminescence assay. The Wilcoxon signed-rank sum test was used to compare observations between time points. Kaplan-Meier analysis was used to calculate TTPP dichotomized by cytokine values above or below the median. Pearson's rank correlation coefficient was used to compare continuous variables. RESULTS:Median TTPP was 399 days (range, 114-1641). Median prostate-specific antigen (PSA) at baseline and progression were 8.5 and 5.3?ng/mL, respectively. Twenty-three patients (62%) achieved undetectable PSA with ADT. Castrate levels of testosterone (<50?ng/dL) after 3 months of ADT occurred in 35 patients (95%). TNF-? (P?=?.002), IL-23 (P?=?.002), and CXCL10 (P?=?.001) significantly increased from baseline to post ADT. Certain cytokines correlated longitudinally: TNF-? correlated with IL-23 (r?=?.72; P?

SUBMITTER: Hawley JE 

PROVIDER: S-EPMC6980998 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature